NF1 is a critical regulator of muscle development and metabolism

Human Molecular Genetics

Volumn 23, Issue 5, 2014, Pages 1250-1259

  Sullivan, Kate ^a   El hoss, Jad ^a,b   Quinlan, Kate G R ^a,b   Deo, Nikita ^a,b   Garton, Fleur ^a,b   Seto, Jane T C ^a,b   Gdalevitch, Marie ^a   Turner, Nigel ^d,e   Cooney, Gregory J ^d,e   Kolanczyk, Mateusz ^c   North, Kathryn N ^a,b   Little, David G ^a,b   Schindeler, Aaron ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BODY WEIGHT; BONE AND BONES; BONE RESORPTION; DISEASE MODELS, ANIMAL; GENES, LETHAL; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MICE; MICE, KNOCKOUT; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCLES; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; ORGAN SIZE;

EID: 84894057845     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt515     Document Type: Article

References (38)

1. Friedman, J.M. (2002) Neurofibromatosis 1, clinical manifestations and diagnostic criteria. J. Child. Neurol., 17, 548-554.
2. Schindeler, A. and Little, D.G. (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone, 42, 616-622.
3. Gutmann, D.H., Aylsworth, A., Carey, J.C., Korf, B., Marks, J., Pyeritz, R.E., Rubenstein,A. and Viskochil, D. (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA, 278, 51-57.
4. Kuorilehto, T., Poyhonen, M., Bloigu, R., Heikkinen, J., Vaananen, K. and Peltonen, J. (2005) Decreased bone mineral density and content in neurofibromatosis type 1, lowest local values are located in the load-carrying parts of the body. Osteoporos. Int., 16, 928-936.
5. Lammert, M., Kappler, M., Mautner, V.F., Lammert, K., Storkel, S., Friedman, J.M. and Atkins, D. (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos. Int., 16, 1161-1166.
6. Tucker, T., Schnabel, C., Hartmann, M., Friedrich, R.E., Frieling, I., Kruse, H.P., Mautner, V.F. and Friedman, J.M. (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J. Med. Genet., 46, 259-265.
7. Stevenson, D.A., Zhou, H., Ashrafi, S., Messiaen, L.M., Carey, J.C., D'Astous, J.L., Santora, S.D. and Viskochil, D.H. (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am. J. Hum. Genet., 79, 143- 148.
8. Yu, X., Chen, S., Potter, O.L., Murthy, S.M., Li, J., Pulcini, J.M., Ohashi, N., Winata, T., Everett, E.T., Ingram, D. et al. (2005) Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone, 36, 793-802.
9. Gutmann, D.H., Cole, J.L. and Collins, F.S. (1994) Modulation of neurofibromatosis type 1 gene expression during in vitro myoblast differentiation. J. Neurosci. Res., 37, 398-405.
10. Feldmann, R., Denecke, J., Grenzebach, M., Schuierer, G. and Weglage, J. (2003) Neurofibromatosis type 1, motor and cognitive function and T2-weighted MRI hyperintensities. Neurology, 61, 1725-1728.
11. Dulai, S., Briody, J., Schindeler, A., North, K.N., Cowell, C.T. and Little, D.G. (2007) Decreased bone mineral density in neurofibromatosis type 1, results from a pediatric cohort. J. Pediatr. Orthop., 27, 472-475.
12. Kossler, N., Stricker, S., Rodelsperger, C., Robinson, P.N., Kim, J., Dietrich, C., Osswald, M., Kuhnisch, J., Stevenson, D.A., Braun, T. et al. (2011) Neurofibromin (Nf1) is required for skeletal muscle development. Hum. Mol. Genet., 20, 2697-2709.
13. Stevenson, D.A., Moyer-Mileur, L.J., Carey, J.C., Quick, J.L., Hoff, C.J. and Viskochil, D.H. (2005) Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography. J. Musculoskelet. Neuronal. Interact., 5, 145-149.
14. Souza, J.F., Passos, R.L., Guedes, A.C., Rezende, N.A. and Rodrigues, L.O. (2009) Muscular force is reduced in neurofibromatosis type 1.J. Musculoskelet. Neuronal. Interact., 9, 15-17.
15. Johnson, B.A., MacWilliams, B.A., Carey, J.C., Viskochil, D.H., D'Astous, J.L. and Stevenson, D.A. (2010) Motor proficiency in children with neurofibromatosis type 1. Pediatr. Phys. Ther., 22, 344-348.
16. Tong, J.J., Schriner, S.E., McCleary, D., Day, B.J. and Wallace, D.C. (2007) Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster. Nat. Genet., 39, 476-485.
17. Brannan, C.I., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L., Reid, S.W., Buchberg, A.M., Jenkins, N.A., Parada, L.F. and Copeland, N.G. (1994) Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev., 8, 1019-1029.
18. Chen, J.C., Mortimer, J., Marley, J. and Goldhamer, D.J. (2005) MyoD-cre transgenic mice, a model for conditional mutagenesis and lineage tracing of skeletal muscle. Genesis., 41, 116-121.
19. Bajenaru, M.L., Zhu, Y., Hedrick, N.M., Donahoe, J., Parada, L.F. and Gutmann, D.H. (2002) Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol., 22, 5100-5113.
20. Schindeler, A., Morse, A., Harry, L., Godfrey, C., Mikulec, K., McDonald, M., Gasser, J.A. and Little, D.G. (2008) Models of tibial fracture healing in normal and Nf1-deficient mice. J. Orthop. Res., 26, 1053-1060.
21. El-Hoss, J., Sullivan, K., Cheng, T., Yu, N.Y., Bobyn, J.D., Peacock, L., Mikulec, K., Baldock, P., Alexander, I.E., Schindeler, A. et al. (2012) A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells. J. Bone. Miner. Res., 27, 68-78.
22. Stevenson, D.A. and Yang, F.C. (2011) The musculoskeletal phenotype of the RASopathies. Am. J. Med. Genet. C Semin. Med. Genet., 157, 90-103.
23. Tidyman, W.E., Lee, H.S. and Rauen, K.A. (2011) Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes, developmental consequences of germline Ras/MAPK activation on myogenesis. Am. J. Med. Genet. C Semin. Med. Genet., 157, 104-114.
24. Johnson, B.A., Macwilliams, B., Carey, J.C., Viskochil, D.H., D'Astous, J.L. and Stevenson, D.A. (2012) Lower extremity strength and hopping and jumping ground reaction forces in children with neurofibromatosis type 1. Hum. Mov. Sci., 31, 247-254.
25. Stevenson, D.A., Allen, S., Tidyman, W.E., Carey, J.C., Viskochil, D.H., Stevens, A., Hanson, H., Sheng, X., Thompson, B.A., Okumura, M.J. et al. (2012) Peripheral muscle weakness in RASopathies. Muscle Nerve, 46, 394-399.
26. El Khassawna, T., Toben, D., Kolanczyk, M., Schmidt-Bleek, K., Koennecke, I., Schell, H., Mundlos, S. and Duda, G.N. (2012) Deterioration of fracture healing in the mouse model ofNF1long bone dysplasia. Bone, 51, 651-660.
27. Rhodes, S.D., Wu, X., He, Y., Chen, S., Yang, H., Staser, K.W., Wang, J., Zhang, P., Jiang, C., Yokota, H. et al. (2013) Hyperactive transforming growth factor-b1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J. Bone. Miner. Res., [23 May, Epub ahead of print].
28. Logan, M., Martin, J.F., Nagy, A., Lobe, C., Olson, E.N. and Tabin, C.J. (2002) Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis, 33, 77-80.
29. Lee, I., Pecinova, A., Pecina, P., Neel, B.G., Araki, T., Kucherlapati, R., Roberts, A.E. and Huttemann, M. (2010) A suggested role for mitochondria in Noonan syndrome. Biochim. Biophys. Acta, 1802, 275-283.
30. Kleefstra, T., Wortmann, S.B., Rodenburg, R.J., Bongers, E.M., Hadzsiev, K., Noordam, C., van den Heuvel, L.P., Nillesen, W.M., Hollody, K., Gillessen-Kaesbach, G. et al. (2011) Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway. Eur. J. Hum. Genet., 19, 138-144.
31. Aeby, A., Sznajer, Y., Cave, H., Rebuffat, E., Van Coster, R., Rigal, O. and Van Bogaert, P. (2007) Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency. J. Inherit. Metab. Dis., 30, 827.
32. de Groof, A.J., te Lindert, M.M., van Dommelen, M.M., Wu, M., Willemse, M., Smift, A.L., Winer, M., Oerlemans, F., Pluk, H., Fransen, J.A. et al. (2009) Increased OXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg phenotype. Mol. Cancer, 8, 54.
33. Laforet, P. and Vianey-Saban, C. (2010) Disorders of muscle lipid metabolism, diagnostic and therapeutic challenges. Neuromuscul. Disord., 20, 693-700.
34. Phan, V.T., Ding, V.W., Li, F., Chalkley, R.J., Burlingame, A. and McCormick, F. (2010) The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast andETEAin humans. Mol. Cell. Biol., 30, 2264-2279.
35. Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K. and Parada, L.F. (2002) Neurofibromas in NF1, Schwann cell origin and role of tumor environment. Science, 296, 920-922.
36. Warner, S.E., Sanford, D.A., Becker, B.A., Bain, S.D., Srinivasan, S. and Gross, T.S. (2006) Botox induced muscle paralysis rapidly degrades bone. Bone, 38, 257-264.
37. Garton, F., Seto, J.T., North, K.N. and Yang, N. (2010) Validation of an automated computational method for skeletal muscle fibre morphometry. Neuromusc. Disord., 20, 540-547.
38. MacArthur, D.G., Seto, J.T., Chan, S., Quinlan, K.G., Raftery, J.M., Turner, N., Nicholson, M.D., Kee, A.J., Hardeman, E.C., Gunning, P.W. et al. (2008) AnActn3 knockoutmouseprovides mechanistic insights into the association between a actinin-3 deficiency and human athletic performance. Hum. Mol. Genet., 17, 1076-1086.